AMYLYX PHARMACEUTICALS INC
AMLXNASDAQ๐ #1506 by market capEarnings Nov 5US Equity
$28.68โฒ $0.61 (+2.17%)
๐ After hours$28.68โฒ 0.00%Regular close ยท extended-hours price shownTrack AMLX
Get earnings, price moves & breaking news on Telegram
24hโฒ 2.2%
7dโฒ 0.3%
14dโฒ 3.8%
30dโผ 1.9%
ytdโฒ 137.2%
1yโฒ 106.7%
๐ฆMarket Cap
$3.60B
Small Cap
๐Revenue Growth (YoY)
-100.0%
Declining
๐Gross Margin
0.0%
Thin
๐ตFCF Margin
0.0%
Thin
โ๏ธP/S Ratio
0.0x
Cheap
Otter Score
36
Weak
AMYLYX PHARMACEUTICALS INC
AMLXAnalyst Ratings
Price
$28.68
Total
11
Raised
1
Lowered
1
Avg PT
$52.20
H / L
$57 / $42
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Citigroup | Reiterated | Buy | 2026-10-15 | โ | โ |
Guggenheim | Reiterated | Buy | 2026-08-27 | $57.00 | +98.70% |
Baird | Reiterated | Outperform | 2026-08-19 | โ | โ |
Mizuho | Reiterated | Outperform | 2026-08-19 | โ | โ |
HC Wainwright & Co. | Reiterated | Buy | 2026-08-18 | โ | โ |
B of A Securities | Reiterated | Buy | 2026-02-20 | โ | โ |
Goldman Sachs | Reiterated | Buy | 2025-09-16 | โ | โ |
Leerink Partners | Upgraded | Market Perform โ Outperform | 2025-05-07 | $10.00 | โ65.10% |
Deutsche Bank | Reiterated | Buy | 2024-03-11 | $4.00 | โ86.10% |
Evercore ISI Group | Downgraded | Outperform โ In Line | 2024-03-08 | โ | โ |
SVB Leerink | Reiterated | Outperform | 2022-09-08 | โ | โ |
Institution
Citigroup
Reiterated ยท Buy ยท 2026-10-15
โ
โ
Guggenheim
Reiterated ยท Buy ยท 2026-08-27
$57.00
+98.70%
Baird
Reiterated ยท Outperform ยท 2026-08-19
โ
โ
Mizuho
Reiterated ยท Outperform ยท 2026-08-19
โ
โ
HC Wainwright & Co.
Reiterated ยท Buy ยท 2026-08-18
โ
โ
B of A Securities
Reiterated ยท Buy ยท 2026-02-20
โ
โ
Goldman Sachs
Reiterated ยท Buy ยท 2025-09-16
โ
โ
Leerink Partners
Upgraded ยท Market Perform โ Outperform ยท 2025-05-07
$10.00
โ65.10%
Deutsche Bank
Reiterated ยท Buy ยท 2024-03-11
$4.00
โ86.10%
Evercore ISI Group
Downgraded ยท Outperform โ In Line ยท 2024-03-08
โ
โ
SVB Leerink
Reiterated ยท Outperform ยท 2022-09-08
โ
โ
One row per institution ยท price target from the firm's latest published target